Long
AGLE - Bump & Run formation Long from $5.32/$5.71 to $7.27
AGLE seems breaking out of an upward channel formation like the Pharmaceutical sector itself. It has good insider buying.
We think it has very good upward potential.
* Trade Criteria *
Date First Found- December 26, 2017
Pattern/Why- Downward channel breakout, Bump & Run formation
Entry Target Criteria- Pullback to $5.32 or break above $5.71
Exit Target Criteria- 1st Target $7.27, 2nd Target $9.67
Stop Loss Criteria- $4.74
Indicator Notes- Crossed above its MA lines
Special Note- Very good insider buying
Please check back for Trade updates. (Note: Trade update is little delayed here.)
We think it has very good upward potential.
* Trade Criteria *
Date First Found- December 26, 2017
Pattern/Why- Downward channel breakout, Bump & Run formation
Entry Target Criteria- Pullback to $5.32 or break above $5.71
Exit Target Criteria- 1st Target $7.27, 2nd Target $9.67
Stop Loss Criteria- $4.74
Indicator Notes- Crossed above its MA lines
Special Note- Very good insider buying
Please check back for Trade updates. (Note: Trade update is little delayed here.)
Like what you see? Get full access to our 3X daily members only video/txt alerts & live trading room at smartmoneytrading.com/now
Check out some of our free video examples @ smartmoneytrading.com/insights/
Check out some of our free video examples @ smartmoneytrading.com/insights/
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Like what you see? Get full access to our 3X daily members only video/txt alerts & live trading room at smartmoneytrading.com/now
Check out some of our free video examples @ smartmoneytrading.com/insights/
Check out some of our free video examples @ smartmoneytrading.com/insights/
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.